Download Champions' latest AACR 2025 Poster

 Building 3D ex vivo models as a powerful platform for anti-cancer drug and biomarker discovery 

Advancements in 3D patient-derived organoid (PDO) and xenograft organoid (PDxO) technology have enabled more predictive and physiologically relevant preclinical models for cancer drug development.

This poster highlights Champions Oncology’s CTGx 3D ex vivo platform, which includes a robust pipeline of tumor models derived from over 50 cancer types. These models are supported by comprehensive molecular characterization, including RNA sequencing, IHC, and high-content imaging, making them powerful tools for therapeutic screening, biomarker discovery, and mechanism-of-action studies.

• CTGx 3D models retain critical patient tumor features, including histological architecture and genomic complexity, enabling high translational relevance.

• These models are effective for evaluating therapeutic responses in rare and genetically diverse cancers, supporting model selection and functional biomarker identification.

• Integrating CTGx data into the broader PPMO (Patient Personal Oncology Model) workflow enhances personalized oncology strategies by informing drug development and patient stratification through biologically rich, clinically annotated datasets.